<DOC>
	<DOCNO>NCT00766818</DOCNO>
	<brief_summary>In study , look blood concentration Kaletra HIV positive patient pregnancy . The patient come 4 visit last ~24hrs . These visit take place 20-24 week , 30 week , 32 week 8 week post-partum . At end vist 2 ( week 30 ) , increase dose 2 adult Kaletra tablet , one pediatric Kaletra tablet ( total dose 500/125mg ) . The dose remain increase 2 week post partum , return standard 2 adult tablet ( 400/100mg ) .</brief_summary>
	<brief_title>The Effect Pregnancy Pharmacokinetics Kaletra Tablet</brief_title>
	<detailed_description />
	<mesh_term>Lopinavir</mesh_term>
	<criteria>HIV positive Pregnant ( &lt; 22 week ) Currently take plan start Kaletra ≥18 year age Active opportunistic serious bacterial infection time entry Past present obstetrical complication ( include , limited : placentia previa , eclampsia , confirm birth defect , multiple gestation pregnancy ) Unable maintain medication adherence , define ≥ 80 % dose take visit Currently receive expect receive protease inhibitor conjunction Kaletra® HIV genotype show accumulation protease inhibitor mutation expect result virologic failure Kaletra® OR document virologic failure Kaletra®containing regimen attributable Kaletra® component Chronic hepatitis B and/or C virus infection Cushing 's Syndrome Untreated hypothyroidism hyperthyroidism Serum Creatinine &gt; 1.5 mg/dL Amylase 1.5 time ULN and/or abnormal lipase Direct total bilirubin level &gt; Grade 1 ALT/AST &gt; Grade 2 ( base NIH Division AIDS ( DAIDS ) Table Grading Severity Adverse Events Bicarbonate &gt; Grade 2 ( DAIDS ) Hematology &gt; Grade 2 ( DAIDS ) , except anemia : exclude woman Hb &lt; 9 g/dL and/or HCT , 27.3 % ( &lt; 8.5 mg/dL and/or HCT , 25.6 % currently ZDV ) screening ; subject anemia enroll study must receive start hematinic , include iron folate supplement , immediately upon enrollment continue anemia resolve end pregnancy . The hematinic supplement may discontinue discretion investigator consider continuation would best interest subject . Receiving follow drug : astemizole , terfenadine , rifampin , cisapride , ergot derivative , simvastatin , lovastatin , St. John 's wort , pimozide , midazolam , triazolam , carbamezapine , phenobarbital , phenytoin , dexamethasone</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>